Drugs / IMM-H014
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06216041 | Dec 2023 → Jun 2025 overdue | metabolic dysfunction-associated steatohepatitis | Changchun Intellicrown Pharmaceutical Co. LTD | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07016633 | Jun 2025 → Jun 2027 expected | metabolic dysfunction-associated steatohepatitis | Changchun Intellicrown Pharmaceutical Co. LTD | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMM-H014 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07016633 ↗ |
| Route | Oral | “IMM-H014 /Placebo tablets administered orally once daily under fasted condition.” NCT06216041 ↗ |